medium-term valuation, page-4

Kincella
The back of the envelope analysis is simply the result of commonly available information. If there is a problem with the conclusion then I would dearly like to hear about it as I have now heavily committed to the company! If GSK can ramp up production that quickly then the estimate based on average PE in the industry seems to me to be conservative. All the numbers show is just how significant the problem is. If there is a pandemic then the BTA share price will be the last thing on our minds as the the rest of the market takes one almighty bath. Just talked myself into increasing my own suply of relenza.